Managing rheumatoid arthritis in the primary care setting

Research output: Contribution to journalReview article

Abstract

Rheumatoid arthritis (RA) presents a number of challenges to both patients and physicians. Because primary care physicians (PCPs) treat most patients who have musculoskeletal disorders, they have an important role in the management of RA, particularly in early diagnosis and treatment. Familiarity with the use of disease-modifying antirheumatic drugs (DMARDs) and combination DMARDs as the cornerstones of therapy is essential. PCPs are also in the best position to monitor comorbid disease. Given the potentially devastating complications of RA, disease management requires a comprehensive approach that includes referrals of patients with significant disease comorbidity to rheumatologic specialists.

Original languageEnglish (US)
Pages (from-to)23-28
Number of pages6
JournalDrug Benefit Trends
Volume16
Issue numberSUPPL. C
StatePublished - Jun 1 2004

Fingerprint

Rheumatoid Arthritis
Primary Health Care
Antirheumatic Agents
Primary Care Physicians
Drug Combinations
Disease Management
Comorbidity
Early Diagnosis
Referral and Consultation
Physicians
Therapeutics
Recognition (Psychology)

Keywords

  • Cyclooxygenase inhibitors
  • Disease-modifying antirheumatic drugs
  • Methotrexate
  • NSAIDs
  • Tumor necrosis factor inhibitors

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Managing rheumatoid arthritis in the primary care setting. / Mikuls, Ted R; O'Dell, James Robert.

In: Drug Benefit Trends, Vol. 16, No. SUPPL. C, 01.06.2004, p. 23-28.

Research output: Contribution to journalReview article

@article{0c965f84ec584a5eb54cd8766e248dfb,
title = "Managing rheumatoid arthritis in the primary care setting",
abstract = "Rheumatoid arthritis (RA) presents a number of challenges to both patients and physicians. Because primary care physicians (PCPs) treat most patients who have musculoskeletal disorders, they have an important role in the management of RA, particularly in early diagnosis and treatment. Familiarity with the use of disease-modifying antirheumatic drugs (DMARDs) and combination DMARDs as the cornerstones of therapy is essential. PCPs are also in the best position to monitor comorbid disease. Given the potentially devastating complications of RA, disease management requires a comprehensive approach that includes referrals of patients with significant disease comorbidity to rheumatologic specialists.",
keywords = "Cyclooxygenase inhibitors, Disease-modifying antirheumatic drugs, Methotrexate, NSAIDs, Tumor necrosis factor inhibitors",
author = "Mikuls, {Ted R} and O'Dell, {James Robert}",
year = "2004",
month = "6",
day = "1",
language = "English (US)",
volume = "16",
pages = "23--28",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "SUPPL. C",

}

TY - JOUR

T1 - Managing rheumatoid arthritis in the primary care setting

AU - Mikuls, Ted R

AU - O'Dell, James Robert

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Rheumatoid arthritis (RA) presents a number of challenges to both patients and physicians. Because primary care physicians (PCPs) treat most patients who have musculoskeletal disorders, they have an important role in the management of RA, particularly in early diagnosis and treatment. Familiarity with the use of disease-modifying antirheumatic drugs (DMARDs) and combination DMARDs as the cornerstones of therapy is essential. PCPs are also in the best position to monitor comorbid disease. Given the potentially devastating complications of RA, disease management requires a comprehensive approach that includes referrals of patients with significant disease comorbidity to rheumatologic specialists.

AB - Rheumatoid arthritis (RA) presents a number of challenges to both patients and physicians. Because primary care physicians (PCPs) treat most patients who have musculoskeletal disorders, they have an important role in the management of RA, particularly in early diagnosis and treatment. Familiarity with the use of disease-modifying antirheumatic drugs (DMARDs) and combination DMARDs as the cornerstones of therapy is essential. PCPs are also in the best position to monitor comorbid disease. Given the potentially devastating complications of RA, disease management requires a comprehensive approach that includes referrals of patients with significant disease comorbidity to rheumatologic specialists.

KW - Cyclooxygenase inhibitors

KW - Disease-modifying antirheumatic drugs

KW - Methotrexate

KW - NSAIDs

KW - Tumor necrosis factor inhibitors

UR - http://www.scopus.com/inward/record.url?scp=3042592872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042592872&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:3042592872

VL - 16

SP - 23

EP - 28

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - SUPPL. C

ER -